Jefferies analyst Akash Tewari said Takeda’s (TAK) early psoriasis Phase 2b data "looks encouraging," but "not clearly better" than data from Bristol-Myers (BMY) for Sotyku. While the firm believes Sotyku/deucra is "an excellent oral" therapy, and a multi-billion dollar opportunity for Bristol, there are next-gen tyk2s in development that may be able to show an improved therapeutic window, said Jefferies, which has a Hold rating and $62 price target on Bristol-Myers shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol Myers Squibb put volume heavy and directionally bearish
- Cantor biopharma/biotech analysts to hold analyst/industry conference call
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Jefferies starts ‘optically cheap’ Bristol-Myers at Hold on structural concerns
- Bristol-Myers initiated with a Hold at Jefferies